Form 8-K - Current report:
SEC Accession No. 0001104659-22-119551
Filing Date
2022-11-16
Accepted
2022-11-16 16:29:31
Documents
12
Period of Report
2022-11-15
Items
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2230665d1_8k.htm   iXBRL 8-K 26910
  Complete submission text file 0001104659-22-119551.txt   198783

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA apre-20221115.xsd EX-101.SCH 3024
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE apre-20221115_lab.xml EX-101.LAB 34476
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE apre-20221115_pre.xml EX-101.PRE 22589
6 EXTRACTED XBRL INSTANCE DOCUMENT tm2230665d1_8k_htm.xml XML 3645
Mailing Address 535 BOYLSTON STREET BOSTON MA 02116
Business Address 535 BOYLSTON STREET BOSTON MA 02116 6095104718
Aprea Therapeutics, Inc. (Filer) CIK: 0001781983 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39069 | Film No.: 221395505
SIC: 2834 Pharmaceutical Preparations